GSK plc
Customers
0
None disclosed
Suppliers
4
0 disclosed
Latest period
Mar 31, 2025
10-Q filed 2025-05-08
Suppliers 4
Companies that disclose GSK as a major customer, as a share of their own revenue. 0 active, 4 lapsed.
| Company | % of their revenue | Est. $ from GSK | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| OncoMed Pharmaceuticals Inc OncoMed Pharmaceuticals Inc |
55% | $5.3M | 3M 2015-03-31 | −5.0pp | Lapsed Last seen 2015-03-31 |
10-Q 2015-05-07 |
GlaxoSmithKline LLC (“GSK”) 55 % * GlaxoSmithKline LLC (“GSK”) 31 % * 65 % GlaxoSmithKline LLC ("GSK") * 60 % 31 % 38 % | ||||||
| CDXS CODEXIS, INC. |
22% | $10.7M | FY 2016-12-31 | +2.0pp | Lapsed Last seen 2016-12-31 |
10-K 2019-03-01 |
GSK * * 22 % GSK * 22 % 20 % GSK 17 % — % — % | ||||||
| MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. |
11.2% | $7.7M | 3M 2023-06-30 | Lapsed Last seen 2023-06-30 |
10-Q 2024-08-08 | |
GSK plc * 11.2 % * * * * | ||||||
| ZYME Zymeworks Inc. |
Named | — | 3M 2025-03-31 | — | Lapsed Last seen 2025-03-31 |
10-Q 2025-05-08 |
At March 31, 2025, the maximum exposure to credit risk for accounts receivable was $24,594, 57% of which was from GSK (December 31, 2024: 95% of receivables from Jazz) and all accounts receivable are due within the next 12 months. | ||||||
Alerts are coming
Get an email when GSK's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.